Edwards Lifesciences to Acquire JenaValve,沛嘉医疗-B Retains Exclusive Rights to Trilogy THV System in Greater China

Zhitong Finance APP reported that Peijia Medical-B (09996) announced on July 24, 2024, JenaValve Technology, Inc. (JenaValve) notified the company that Edwards Lifesciences Corporation has agreed to acquire JenaValve through a merger. Edwards Lifesciences Corporation is a company listed on the New York Stock Exchange and a global leader in patient-focused innovations for structural heart disease and critical care monitoring. The completion of the merger is subject to the terms and conditions set forth in the merger agreement, including customary closing conditions.

JenaValve is a U.S.-based medical device company. In December 2021, the Group obtained the exclusive license to develop, manufacture, and commercialize the JenaValve Trilogy™ Transcatheter Heart Valve System (THV System) for the treatment of aortic regurgitation (AR) and aortic stenosis (AS) in the Greater China region. Subsequently, the company rebranded the technology as TaurusTrio™ and launched a multicenter registrational clinical trial in China targeting severe AR. Patient enrollment for the trial was successfully completed in January 2024.

The merger will not affect the Group's exclusive license with JenaValve or the Group’s rights to develop and commercialize TaurusTrio™. Upon completion of the merger, the Group will retain the aforementioned exclusive license to develop THV systems for AR and AS within the region. The Company believes that the merger reflects strong confidence in the future prospects of utilizing JenaValve technology for treating AR.